![Sample size estimation for clinical trials in de novo Parkinson's disease (PD): Results from the Parkinson's Progression Markers Initiative (PPMI) Study - MDS Abstracts Sample size estimation for clinical trials in de novo Parkinson's disease (PD): Results from the Parkinson's Progression Markers Initiative (PPMI) Study - MDS Abstracts](https://www.mdsabstracts.org/wp-content/uploads/2017/05/0037-002207_001.png)
Sample size estimation for clinical trials in de novo Parkinson's disease (PD): Results from the Parkinson's Progression Markers Initiative (PPMI) Study - MDS Abstracts
![Parkinson's Disease: Current and Future Therapeutics and Clinical Trials: Galvez-Jimenez, Nestor: 9781107053861: Books Parkinson's Disease: Current and Future Therapeutics and Clinical Trials: Galvez-Jimenez, Nestor: 9781107053861: Books](https://images-na.ssl-images-amazon.com/images/I/511KCrQzxML._SX391_BO1,204,203,200_.jpg)
Parkinson's Disease: Current and Future Therapeutics and Clinical Trials: Galvez-Jimenez, Nestor: 9781107053861: Books
Aspen Neuroscience Launches First Patient Screening Study for Planned Clinical Trial of Personalized Cell Replacement in Parkinson's Disease
![Zonisamide improves wearing off in Parkinson's disease without exacerbating dyskinesia: Post hoc analysis of phase 2 and phase 3 clinical trials - Journal of the Neurological Sciences Zonisamide improves wearing off in Parkinson's disease without exacerbating dyskinesia: Post hoc analysis of phase 2 and phase 3 clinical trials - Journal of the Neurological Sciences](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/7e94d60e-eb63-41c6-bf00-cf2a1d9beb84/gr1.jpg)
Zonisamide improves wearing off in Parkinson's disease without exacerbating dyskinesia: Post hoc analysis of phase 2 and phase 3 clinical trials - Journal of the Neurological Sciences
![The NADPARK study: A randomized phase I trial of nicotinamide riboside supplementation in Parkinson's disease - ScienceDirect The NADPARK study: A randomized phase I trial of nicotinamide riboside supplementation in Parkinson's disease - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S1550413122000456-fx1.jpg)
The NADPARK study: A randomized phase I trial of nicotinamide riboside supplementation in Parkinson's disease - ScienceDirect
![NIH launches partnership to improve success of clinical trials for patients with Parkinson's disease | National Institutes of Health (NIH) NIH launches partnership to improve success of clinical trials for patients with Parkinson's disease | National Institutes of Health (NIH)](https://www.nih.gov/sites/default/files/styles/featured_media_breakpoint-medium/public/research-training/initiatives/amp/AMP-parkinsons.png?itok=8YS_wgIE×tamp=1517237384)
NIH launches partnership to improve success of clinical trials for patients with Parkinson's disease | National Institutes of Health (NIH)
![Upcoming Clinical Trial Will Test New Cell Therapy for Parkinson's Disease in Humans | Memorial Sloan Kettering Cancer Center Upcoming Clinical Trial Will Test New Cell Therapy for Parkinson's Disease in Humans | Memorial Sloan Kettering Cancer Center](https://www.mskcc.org/sites/default/files/styles/large/public/node/216883/3x2/studer-and-tabar.jpg)
Upcoming Clinical Trial Will Test New Cell Therapy for Parkinson's Disease in Humans | Memorial Sloan Kettering Cancer Center
![The Outlook Is Encouraging: Researchers Evaluate a Pipeline of Clinical Trials Targeting Parkinson's Disease | Journal of Parkinson's Disease The Outlook Is Encouraging: Researchers Evaluate a Pipeline of Clinical Trials Targeting Parkinson's Disease | Journal of Parkinson's Disease](https://www.iospress.nl/wp-content/uploads/2020/08/JPD10-3_PR3_image.jpg)
The Outlook Is Encouraging: Researchers Evaluate a Pipeline of Clinical Trials Targeting Parkinson's Disease | Journal of Parkinson's Disease
![Effectiveness of home-based and remotely supervised aerobic exercise in Parkinson's disease: a double-blind, randomised controlled trial - The Lancet Neurology Effectiveness of home-based and remotely supervised aerobic exercise in Parkinson's disease: a double-blind, randomised controlled trial - The Lancet Neurology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/3ece7627-d329-4a3e-8c88-986f5ea97a3e/gr1.gif)